The Valley Desk

ArticleArthritis & rheumatology (Hoboken, N.J.)Published

Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial

Read the publication ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Perelman School of Medicine, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Arthritis & rheumatology (Hoboken, N.J.)
Published
PubMed ID
43012507
Added to directory
Source checked

Report a correction or request removal